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Abstract
We propose a categorical matrix factorization method to infer latent diseases from
electronic health records (EHR) data in an unsupervised manner. A latent disease is
defined as an unknown biological aberration that causes a set of common symptoms
for a group of patients. The proposed approach is based on a novel double feature
allocation model which simultaneously allocates features to the rows and the columns
of a categorical matrix. Using a Bayesian approach, available prior information on
known diseases greatly improves identifiability and interpretability of latent diseases.
This includes known diagnoses for patients and known association of diseases with
symptoms. We validate the proposed approach by simulation studies including mis-
specified models and comparison with sparse latent factor models. In the application
to Chinese EHR data, we find interesting results, some of which agree with related
clinical and medical knowledge.
Keywords: Indian buffet process, overlapping clustering, tripartite networks, patient-level
inference, matrix factorization.
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1 Introduction
Electronic health records (EHR) data electronically document medical diagnoses and clinical
symptoms by the health care providers. The digital nature of EHR automates access to
health information and allows physicians and researchers to take advantage of a wealth of
data. Since its emergence, EHR has motivated novel data-driven approaches for a wide
range of tasks including phenotyping, drug assessment, natural language processing, data
integration, clinical decision support, privacy protection and data mining (Ross et al. ,
2014). In this article, we propose a double feature allocation (DFA) model for latent disease
phenotyping. A latent disease is defined as an unknown biological aberration that causes a
set of common symptoms for a group of patients. The DFA model is a probability model on
a categorical matrix with each entry representing a symptom being recorded for a specific
patient. The proposed model is based on an extension of the Indian buffet process (IBP,
Griffiths & Ghahramani 2006). The generalization allows many-to-many patient-disease and
symptom-disease relationships and does not require fixing the number of diseases a priori.
Existing diagnostic information is incorporated in the model to help identify and interpret
latent diseases. DFA can be also viewed as an alternative representation of categorical matrix
factorization or as inference for an edge-labeled random network. While recent phenotyping
methods (Halpern et al. , 2016; Henderson et al. , 2017) are mostly performed via supervised
learning, the proposed DFA is an unsupervised approach that aims to identify latent diseases.
The proposed approach builds on models for Bayesian inference of hidden structure, in-
cluding nonparametric mixtures, as reviewed, for example, in Favaro & Teh (2013); Barrios
et al. (2013), graphical models (Green & Thomas, 2013; Dobra et al. , 2011), matrix fac-
torization (Rukat et al. , 2017), and random partitions and feature allocation as discussed
and reviewed, for example, in Broderick et al. (2013) or Campbell et al. (2018). We ex-
plain below how graphs and matrix factorization relate to the proposed model and inference.
The proposed inference is motivated by EHR data that were collected in routine physical
examinations for residents in a city in northeast China in 2016. The dataset contains both,
information on some diagnoses that were recorded by the physicians, as well as symptoms
from laboratory test results, such as metabolic and lipid panels. The diagnoses are binary
variables indicating whether a patient has a disease or not, and includes only some selected
2
diseases. Data on symptoms are categorical variables with the number of categories de-
pending on the specific type of the symptom. For example, heart rate is divided into three
categories, low, normal and high, whereas low density lipoprotein is classified as normal vs
abnormal (elevated) levels. The availability of both, diagnostic and symptomatic informa-
tion provides a good opportunity to detect latent diseases via statistical modeling, that is, to
infer latent disease information in addition to the disease diagnoses that are already included
in the data. The proposed DFA model simultaneously allocates patients and symptoms into
the same set of latent features that are interpreted as latent diseases.
Many generic methods have been developed for identifying latent patterns, which can be
potentially adopted for disease mining. We briefly review related literature. Graphical models
(Lauritzen, 1996) succinctly describe a set of coherent conditional independence relationships
of random variables by representing their distribution as a graph. Conditional independence
structure can be directly read off from the graph through the notion of graph separation.
Graphical models can reveal certain latent patterns of symptoms. For example, by extracting
cliques (maximal fully connected subgraphs) from an estimated graph of symptoms one can
identify symptoms that are tightly associated with each other. An underlying disease that
is linked to these symptoms may explain the association. However, this approach provides
no patient-level inference since the patient-disease relationship is not explicitly modeled and
the choice of using cliques rather than other graph summaries remains arbitrary.
Clustering models partition entities into mutually exclusive latent groups (clusters). Nu-
merous methods have been developed, including algorithm-based approaches such as k-
means, and model-based clustering methods such as finite mixture models (Richardson &
Green, 1997; Miller & Harrison, 2018) and infinite mixture models (Lau & Green, 2007;
Favaro & Teh, 2013; Barrios et al. , 2013, for example). Partitioning symptoms, similar
to graphical models, may discover latent diseases that are related to subsets of symptoms
whereas clustering patients suggests latent diseases that are shared among groups of patients.
Jointly clustering both symptoms and patients, also known as bi-clustering (Hartigan, 1972;
Li, 2005; Xu et al. , 2013), allows one to simultaneously learn patient-disease relationships
and symptom-disease relationships. The main limitation of clustering methods is the strin-
gent assumption that each patient and symptom is related to exactly one disease. Moreover,
most biclustering methods deal with continuous data (Guo, 2013).
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Feature allocation models (Griffiths & Ghahramani, 2006; Broderick et al. , 2013), also
known as overlapping clustering, relaxes the restriction to mutually exclusive subsets and
allocates each unit to possibly more than one feature. When simultaneously applied to both,
patients and symptoms, it is referred to as overlapping biclustering or DFA. Like biclustering,
most of the existing DFA approaches only handle continuous outcomes. See Pontes et al.
(2015) for a recent review and references therein. Only few methods, such as Wood et al.
(2006) and Uitert et al. (2008) can be applied to discrete data, but are constrained to
binary observations, which is unsuitable for our application with categorical observations.
The proposed DFA extends existing methods to general categorical data, automatic selection
of the number of features, and incorporation of prior information.
Latent factor models construct a low-rank representation of the covariance matrix of
a multivariate normal distribution. Latent factor models assume that the variables are
continuous and follow independent normal distributions centered on latent factors multiplied
by factor loadings. Imposing sparsity constraints (Bhattacharya & Dunson, 2011; Rocˇkova´
& George, 2016), latent factor models can be potentially adopted for the discovery of latent
causes. However, the assumptions of normality and linear structure are often violated in
practice and it is not straightforward to incorporate known diagnostic information into latent
factor models. Principal component analysis has the same limitations.
Matrix factorization is closely related to factor models but not necessarily constrained to
multivariate normal sampling distribution. The most relevant variation of matrix factoriza-
tion for our application is binary/boolean matrix factorization (Meeds et al. , 2007; Zhang
et al. , 2007; Miettinen et al. , 2008) which decomposes a binary matrix into two low-rank
latent binary matrices. The proposed DFA can be viewed as categorical matrix factorization
which includes binary matrix factorization as a special case.
The contributions of this paper are three-fold: (1) we introduce a novel categorical matrix
factorization model based on DFA; (2) we incorporate prior information to identify and
interpret latent diseases; and (3) we make inference on the number of latent diseases, patient-
disease relationships and symptom-disease relationships.
4
1.1 Motivating case study: electronic health records
EHR data provides great opportunities for data-driven approaches in early disease detection,
screening and prevention. We consider EHR data for n = 1000 adults aged from 45 to 102
years with median 71 years. The dataset is based on physical examinations of residents in
some districts of a city in northeast China, and was collected in 2016. The sample size of
n=1000 corresponds to several weeks’ worth of data. In this paper we focus on developing
model-based inference, including full posterior simulation and summaries and therefore focus
on a moderate sample size. We will show how meaningful inference about disease discovery
is possible with such data. Extension to larger datasets is discussed in Section 7. As in any
work with EHR data, model-based inference needs to be followed up by expert judgment
to confirm the proposed latent diseases and other inference summaries. Once confirmed,
inferred disease relationships become known prior information for future weeks. This is how
we envision an on-site implementation of the proposed methods.
The data contain blood test results measured on 39 testing items which are listed in Table
1. Figure 1(a) shows the empirical correlation structure of the testing items as a heatmap
with green, black, and red colors indicating positive, negligible and negative correlations.
With appropriate ordering of the test items, one can see some patterns on the upper-left
corner of the heatmap. However, the patterns seem vague and have no clear interpretation.
The heatmap of the standardized data is shown in Figure 1(b) with green, black and red
colors indicating values above, near and below the average. Next we cluster the data using
a K-means algorithm with K = 14 (the number of latent diseases identified in later model-
based inference), applied to both, rows and columns of the data matrix. The clusters find
some interesting structures. For example, indexing the submatrices in the heatmap by row
and column blocks, the values in block (9,9) tend to be above the average, whereas the values
in the block (1,4) tend to be below the average. However, there are at least two difficulties in
interpreting the clusters as latent diseases. Firstly, there is no absolute relationship between
the normal range of a testing item and its population average. A deviation from the average
does not necessarily indicate an abnormality. Likewise, average values of testing items,
especially those related to common diseases such as hypertension, are not necessarily within
the normal range. For instance, the mean and the median of systolic blood pressure in our
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dataset are 147 mm Hg and 145 mm Hg, both of which are beyond the threshold 140 mm
Hg for hypertension (the high blood pressure values might be related to the elderly patient
population). Secondly, the exploratory analysis with K-means does not explicitly model
patient-disease relationships and symptom-disease relationships. For example, one may be
tempted to interpret each column block as a latent disease. As a consequence, each testing
item has to be associated with exactly one disease and the patient-disease relationship is
unclear. If instead, we define a latent disease by the row blocks, then each patient has to
have exactly one disease and the symptom-disease relationship is ambiguous.
We can slightly improve interpretability by incorporating prior information. Specifically,
each testing item comes with a reference range which we use to define symptoms: a symptom
is an item beyond the reference range. In essence, we convert the original data matrix into a
ternary matrix which is shown in Figure 1(c). The first difficulty is resolved but the second
difficulty remains. For instance, the 6th column seems to suggest a disease with elevated total
cholesterol and low density lipoproteins, which is also found in our later analysis with the
proposed DFA. However, just as in Figure 1(b), it is hard to judge which blocks meaningfully
represent latent disease since patient-disease relationships and symptom-disease relationships
are not explicitly modeled. Besides the requirement of specifying the number of clusters,
K-means is unsuitable for the task that we are pursuing in this paper.
Alternatively, instead of discretization, we can scale and center test items at the midpoint
of each reference range. We show the heatmap in Figure 1(d) where the rows and the columns
are arranged in the same way as in Figure 1(c). However, just as previous cases, the same
limitation of interpretability still applies.
The proposed DFA addresses all these issues, some of which have direct impact in prac-
tice. For example, explicit modeling of patient-disease relationships by DFA can be used
to estimate the prevalence of latent diseases in the target population, which is helpful for
healthcare policymakers. Finally, we emphasize that the gold standard of phenotyping re-
mains the judgment by trained clinicians. The inference from DFA, however, is an important
decision tool to facilitate this process, for instance, through the data-assisted personalized
diagnosis support system (Section 6.3).
The remainder of this paper is organized as follows. We introduce the proposed DFA
model in Section 2 and its alternative interpretations in Section 3. Posterior inference is
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Table 1: Blood test items. Acronyms are given within parentheses. Ternary symptoms (after
applying the reference range) are in bold face. CV indicates coefficient of variation, “dist”
is distribution, “mn” is mean, “ct”is count, and “conc” is concentration.
alanine aminotransferase (ALT) aspartate aminotransferase (AST) total bilirubin (TB)
total cholesterol (TC) triglycerides low density lipoproteins (LDL)
high density lipoproteins (HDL) urine pH (UrinePH) mn corpuscular hemoglobin conc (MCHC)
% of monocytes (%MON) alpha fetoprotein (AFP) carcinoembryonic antigen (CEA)
number of monocytes (#MON) plateletcrit (PCT) CV of platelet dist. (PDW-CV)
% of eosinophil (%Eosinophil) basophil ct (#Basophil) % of basophil (%Basophil)
platelet large cell ratio (P-LCR) platelets systolic blood pressure (Systolic)
% of granulocyte (%GRA) body temperature (BodyTemperature) leukocytes
hemoglobin creatinine blood urea nitrogen (BUN)
glucose diastolic blood pressure (Diastolic) heart rate (HeartRate)
erythrocytes hematocrit (HCT) uric acid (UricAcid)
% of lymphocyte (%LYM) mn corpuscular volume (MCV) mn corpuscular hemoglobin (MCH)
lymphocyte ct (#LYM) granulocyte ct (#GRA) mn platelet volume (MPV)
described in Section 4. Simulation studies and an EHR data analysis are presented in
Sections 5 and 6. We conclude this paper by a discussion in Section 7.
2 Double Feature Allocation Model
DFA can be applied to any categorical matrix. For simplicity, and in anticipation of the
application to EHR, we will describe our model for binary and ternary matrices. Let
yil ∈ {−1, 0,+1} and zij ∈ {0, 1} for i = 1, . . . , n, l = 1, . . . , q, and j = 1, . . . , p. In the
EHR dataset, yil denote the observation for patient i for a symptom that can be naturally
trichotomized into low (yil = −1), normal (yil = 0) and high (yil = +1) levels. Similarly, zij
denotes a symptom that is dichotomized into normal (zij = 0) vs abnormal (zij = 1) levels.
We assume that a patient experiences certain symptoms when he/she has diseases that are
related to those symptoms. In other words, the patient-symptom relationships are thought
to be generated by two models: a patient-disease model and a symptom-disease model.
2.1 Patient-disease (PD) model
The patient-disease relationships are defined by a binary matrix A = (αik) ∈ {0, 1}n×K˜ with
αik = 1 meaning patient i has disease k. We start the model construction assuming a fixed
number K˜ of diseases, to be relaxed later (and we reserve the notation K for the relaxation).
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Figure 1: Heatmap of blood test data. In Panel (a), the correlation structure of the testing
items is shown with green, black, and red colors indicating positive, negligible and negative
correlations. Diagonal entries are set to 0. In Panels (b), (c) and (d), the rows and columns
are ordered according to K-means with K = 14. The columns are the testing items and
the rows are patients. In Panel (b), the EHR data is standardized. Green, black and red
colors represent values above, near and below the average or the midpoint. In Panel (c), the
EHR data is transformed to a categorical matrix based on a trichotomization with respect
to a reference range. Green, black and red colors indicate above, within, below the range,
respectively. In panel (d), the EHR data is scaled and centered at the midpoint of the
reference range (the order of rows and columns is the same as in Panel (c)).
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Conditional on K˜, αik are assumed to be independent Bernoulli random variables, αik | pik ∼
Ber(pik) with pik following a conjugate beta prior, pik ∼ Beta(m/K˜, 1). Here m is a fixed
hyperparameter. Marginalizing out pik,
p(A) =
K˜∏
k=1
mΓ(rk +
m
K˜
)Γ(n− rk + 1)
K˜ Γ(n+ 1 + m
K˜
)
,
where rk =
∑n
i=1 αik is the sum of the ith column of A.
However, the number of latent diseases is unknown in practice and inference on K˜ is of
interest. Let Hn =
∑n
i=1 1/i be the n-th harmonic number. Next, take the limit K˜ →∞ and
remove columns of A with all zeros. This step is not trivial and needs careful consideration
of equivalence classes of binary matrices; details can be found in Section 4.2 of Griffiths &
Ghahramani (2011). Let K denote the number of non-empty columns. The resulting matrix
A follows an IBP(m) prior (without a specific column ordering), with probability
p(A) =
mK exp{−mHn}
K!
K∏
k=1
Γ(rk)Γ(n− rk + 1)
Γ(n+ 1)
. (1)
Since K is random and unbounded, we do not need to specify the number of latent diseases
a priori. And with a finite sample size, the number K of non-empty diseases is finite with
probability one. See, for example, Griffiths & Ghahramani (2011) for a review of the IBP,
including the motivation for the name based on a generative model. We only need two results
that are implied by this generative model. Let r−i,k denote the sum in column k, excluding
row i. Then the conditional probability for αik = 1 is
p(αik = 1 | α−i,k) = r−i,k/n, (2)
provided r−i,k > 0, where α−i,k is the kth column of A excluding ith row. And the distri-
bution of the number of new features (disease) for each row (patient) is Poi(m/n).
2.2 Symptom-disease (SD) model
A disease may trigger multiple symptoms and a symptom may be related to multiple diseases.
The SD model allows both. Let K again denote the number of latent diseases. The SD
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model inherits K from the PD model. For binary symptoms, we generate a binary (p×K)
matrix B = [βjk], βjk ∈ {0, 1}, from independent Bernoulli distributions, βjk ∼ Ber(ρ) with
ρ ∼ Beta(aρ, bρ). Similarly, for ternary symptoms, we generate a (q × K) ternary matrix
C = [γlk], γlk ∈ {−1, 0, 1}, from independent categorical distributions γlk ∼ Categ(pi) with
pi ∼ Dir(φ−1, φ0, φ+1).
We have considered that βjk ∼ Ber(ρ) and ρ ∼ Beta(aρ, bρ), that is, all binary symptoms
(similarly for ternary symptoms) have the same probability of being triggered by any disease
a priori, which implies that the βjk’s are exchangeable across symptoms and diseases. The
construction with the unknown hyperparameter ρ allows for automatic multiplicity control
(Scott & Berger, 2010). However, exchangeability does not necessarily hold in all cases.
For example, symptoms such as fever are more common than symptoms such as chest pain.
If desired, such heterogeneity across symptoms can be incorporated in the proposed model
by setting βjk ∼ Ber(ρj). In addition, the beta prior on ρj can be adjusted according to
the prior knowledge of the importance of each symptom j. Letting λj = Φ
−1(ρj) denote a
probit transformation of ρj, one can introduce dependence across symptoms by a hierarchical
model,
λj | λ, σ2 ∼ N(λ, σ2) (3)
λ ∼ p(λ) ∝ 1, σ2 ∼ IG(aσ, bσ)
We explore this approach in a simulation study reported in the Supplementary Material A.
A similar strategy can be used to accomodate heterogeneity across diseases, in which case
we assume βjk ∼ Ber(ρk).
Note that A, B and C have the same number of columns because they share the same
latent diseases. In the language of the Indian restaurant metaphor, each dish (disease) cor-
responds to a combination of ingredients (symptoms). Some ingredients come at spice levels
{−1, 1}, if selected. We have now augmented model (1) by matching each subset of patients,
i.e., each disease, with a subset of symptoms defined in B and C. As a result, each disease,
or feature, is defined as a pair of random subsets of patients and symptoms, respectively. We
therefore refer to the model as double feature allocation (DFA). In this construction we have
defined the joint prior ofA,B andC using the factorization p(A,B,C) = p(A)p(B,C | A),
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i.e. first assuming an IBP prior for A, and then defining a prior on B and C conditional on
A (through K, the number of columns of A). In principle, the joint prior can alternatively
be factored as p(A,B,C) = p(B,C)p(A | B,C), in which case we start the construction
with a prior p(B,C). However, the categorical nature of C complicates this construction
and we therefore prefer the earlier factorization.
The main variations in the construction, compared to traditional use of the IBP as prior
for a binary matrix, is the use of matched subsets of patients and symptoms for each feature,
the mix of binary and categorical items, and the specific sampling model, as it arises in the
motivating application.
2.3 Sampling model
Once we generate the PD and SD relationships, the observed data matrix which records the
symptoms for each patient is generated by the following sampling models. Let αi denote
the ith row of A, βj the jth row of B as a column vector, and γl the lth row of C, written
as a column vector. We assume conditionally independent Bernoulli distributions for zij
zij|αi,βj,Wj, ζj ∼ Ber
{
exp(αiWjβj + ζj)
1 + exp(αiWjβj + ζj)
}
, (4)
withWj = diag(wj1, . . . , wjK) where wjk is constrained to be positive, so that the probability
of experiencing symptom j for patient i always increases if a patient has a disease k that
triggers the symptom. The parameter ζj captures the remaining probability of symptom j
that is unrelated to any disease. One could alternatively include the weight already in B
(and C). We prefer separating the formation of the random subsets which define the features
versus the weights which appear in the sampling model.
Similarly, we assume conditionally independent categorical distributions for yil. Let
Cat(pi1, pi2, pi3) denote a categorical distribution with probabilities pi1, pi2, pi3 for three out-
comes. Also let γ+l = I(γl = +1) and γ
−
l = I(γl = −1) with I(·) being the element-wise
indicator function. We assume
yil | αi,γl,W−l ,W+l , η+l , η−l ∼ Cat
(
MeαiW
−
l γ
−
l +η
−
l , M, MeαiW
+
l γ
+
l +η
+
l
)
, (5)
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withM being the normalization constant,W−l = diag(w
−
l1, . . . , w
−
lK) andW
+
l = diag(w
+
l1, . . . , w
+
lK),
where w−lk, w
+
lk are also constrained to be positive, and η
−
l and η
+
l have interpretations similar
to ζj.
We complete the model by assigning vague priors on hyperparameters, ζj, η
−
l , η
+
l ∼
N(0, τ 2) with τ = 100 and wjk, w
−
lk, w
+
lk ∼ Gamma(1, τw) with variance τ 2w = 100. A
brief sensitivity analysis for the choice of these hyperparameters is shown in Supplementary
Material A.
2.4 Incorporating prior knowledge
Available diagnostic information is easily incorporated in the proposed model. We fix the first
K0 columns of A to represent available diagnoses related to K0 known diseases. Specifically,
we label the known diseases as 1, . . . , K0 and set αik = 1 if and only if individual i is diagnosed
with disease k for k = 1, . . . , K0. Similarly, known SD relationships are represented by fixing
corresponding columns of B or C.
A simple example with 11 patients and 6 ternary symptoms is shown in Figure 2 for
illustration. There are 4 diseases, each represented by one color (corresponding to the dashed
blocks inside the matrix in Figure 2). Importantly, patients and symptoms can be linked
to multiple diseases. For example, patient 9 has both, the blue and the green disease,
and symptom 4 can be triggered by either the red or the green disease. Available prior
information is incorporated in this example. For instance, if patients 9, 10, 11 are diagnosed
with the blue disease, they will be grouped together deterministically (represented by the
blue solid line on the side). Likewise, if the yellow disease is known to lead to symptoms 1
and 6, we fix them in the model (represented by the yellow solid lines on the top).
3 Alternative Interpretations
The proposed DFA is closely related to matrix factorization and random networks. We
briefly discuss two alternative interpretations of DFA for the case of the observed data being
ternary. Binary outcomes are a special case of ternary outcomes; generalization to more
than three categories is straightforward. We use the same toy example as in Section 2.4 to
illustrate the alternative interpretations.
12
1 -1 0 -1 0 0 +1
2 -1 0 0 0 0 +1
3 -1 +1 +1 -1 0 +1
4 0 +1 +1 -1 0 0
5 +1 +1 0 -1 0 -1
6 0 +1 +1 -1 +1 -1
7 0 +1 0 -1 +1 -1
8 +1 0 0 -1 +1 0
9 -1 -1 0 -1 0 -1
10 -1 -1 0 0 +1 0
11 -1 -1 0 +1 0 0
1 2 3 4 5 6
Pa
tie
nt
s
Symptoms
Figure 2: Illustration of DFA for ternary symptoms. The lines on the side/top indicate
the grouping of patients/symptoms by diseases. Each disease is represented by one color.
Dashed lines are latent whereas solid lines are known.
Categorical matrix factorization (CMF). DFA can be viewed as a CMF. Merging W and
γ, model (5) probabilistically factorizes an (n × q) categorical matrix Y into an (n × K)
low-rank binary matrix A and an K × q low-rank nonnegative matrix D = (δkl) where
K < min(n, q), δkl = w
−
lkγ
−
lk + w
+
lkγ
+
lk, γ
−
lk = I(γlk = −1) and γ+lk = I(γlk = +1). From (5),
log{p(yil = y)} = c+

αiδ
−
l + η
−
l for y = −1
αiδ
+
l + η
+
l for y = +1
0 for y = 0
(6)
where δl = (δ1l, . . . , δKl)
T , δ−l = δl ◦ I(γl = −1), δ+l = δl ◦ I(γl = +1) with element-wise
multiplication ◦, and c = − log{exp(αiδ−l + η−l ) + exp(αiδ+l + η+l ) + 1}. Figure 3 illustrates
the factorization. The matrix A describes the PD relationships. D− and D+ characterize
the SD relationships where D− = D ◦ I(C = −1) and D+ = D ◦ I(C = +1). The number
of diseases is less than the number of patients and the number of symptoms.
Edge-labeled random networks. DFA can be also interpreted as inference for a random
network with labeled edges. The observed categorical matrix Y is treated as a categorical
adjacency matrix which encodes a bipartite random network. Patients form one set of
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Figure 3: Categorical matrix factorization as an alternative representation of DFA in Figure
2. D− = D ◦ I(C = −1) and D+ = D ◦ I(C = +1). Diseases correspond to the columns of
A and the rows of D− and D+. They are represented by the same set of colors as in Figure
2.
nodes and symptoms form another set. The edge labels correspond to the categories in
Y . See the bipartite network on the upper portion of Figure 4 where the two labels (+1,
−1) are respectively represented by arrow heads and flat bars. DFA assumes that the
observed bipartite graph is generated from a latent tripartite graph (given in the lower
portion of Figure 4). Inference under the DFA model reverses the data generation process.
The tripartite graph introduces an additional set of (latent) nodes corresponding to diseases.
The edges between patients (symptom) and diseases indicate PD (SD) relationships. Prior
PD and SD knowledge is represented by fixing the corresponding edges (solid lines in Figure
4).
4 Posterior Inference
The model described in Section 2 is parameterized by
θ = {A,B,C, {Wj, ζj}pj=1, {W−l ,W+l , η−l , η+l }ql=1}.
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Figure 4: Edge-labeled random networks as an alternative representation of the DFA in
Figure 2. The observed bipartite graph (top) is assumed to be generated by the latent
tripartite graph (bottom). DFA addresses the inverse problem. Circles are patients, squares
are symptoms and triangles are diseases whose colors have the same interpretations as in
Figure 2. Dashed lines are latent whereas solid lines are known/observed. An undirected
edge connecting patients and diseases is binary. Edges with arrow head or flat bars represent
different types of SD relationships.
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Posterior inference is carried out by Markov chain Monte Carlo (MCMC) posterior simula-
tion. All parameters except A can be updated with simple Metropolis-Hasting transition
probabilities. Sampling A is slightly more complicated because the dimension of the param-
eter space can change. We therefore provide details of the transition probability for updating
A. In the implementation, for easier bookkeeping, we set a large upper bound K∨ = 50 for
the number of latent diseases; it is never reached during the course of the MCMC.
MCMC
We use superscript (t) to index the state θ across iterations. Initialize θ(0). For t = 0, . . . , T−
1, do
(1) Update A(t+1). We scan through each row, i = 1, . . . , n, of A = A(t).
(1a) Update existing diseases k = 1, . . . , K. If α−i,k = 0, drop disease k; otherwise,
sample αik from the full conditional distribution. For j = 0, 1
p(αik = j | ·) ∝ p(αik = j | α−i,k) p(zi | αik = j,αi,−k,B, {Wj, ζj}pj=1) ×
p(yi | αik = j,αi,−k,C, {W−l ,W+l , η−l , η+l }ql=1)
= p(αik = j | α−i,k)
p∏
j=1
p(zij | αik = j,αi,−k,βj,Wj, ζj) ×
q∏
l=1
p(yil | αik = j,αi,−k,γl,W−l ,W+l , η−l , η+l )
where the factors in the last equation are defined in (2), (4) and (5), respectively.
(1b) Propose new diseases. The proposed new diseases are unique to patient i only,
i.e., αik = 1 and α−i,k = 0. We first draw k∗ ∼ Poi(m/n). If k∗ = 0, go
to the next step. Otherwise, we propose a set of new disease-specific param-
eters β∗k = (β
∗
1k, . . . , β
∗
pk)
T , γ∗k = (γ
∗
1k, . . . , γ
∗
qk)
T , {w∗jk}pj=1, {w−∗lk , w+∗lk }ql=1 for
k = K + 1, . . . , K + k∗ from their respective prior distributions. We accept the
new disease(s) and the disease-specific parameters, with probability
min
{
1,
∏p
j=1 p(zij | α∗i ,β∗j ,W ∗j , ζj)∏p
j=1 p(zij | α(t)i ,β(t)j ,W (t)j , ζj)
∏q
l=1 p(yil | α∗i ,γ∗l ,W−∗l ,W+∗l , η−l , η+l )∏q
l=1 p(yil | α(t)i ,γ(t)l ,W−(t)l ,W+(t)l , η−l , η+l )
}
,
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whereα∗i = (α
(t)
i , 1, . . . , 1), β
∗
j = (β
(t)T
j , β
∗
j,K+1, . . . , β
∗
j,K+k∗)
T , γ∗l = (γ
(t)T
l , γ
∗
l,K+1, . . . , γ
∗
l,K+k∗)
T ,
W ∗j = blkdiag(W
(t)
j , w
∗
j,K+1, . . . , w
∗
j,K+k∗),W
−∗
l = blkdiag(W
−(t)
l , w
−∗
l,K+1, . . . , w
−∗
l,K+k∗)
and W+∗l = blkdiag(W
+(t)
l , w
+∗
l,K+1, . . . , w
+∗
l,K+k∗). Note that the acceptance prob-
ability only involves the likelihood ratio because prior and proposal probabilities
cancel out. If the new disease is accepted, we increase K by k∗.
(2) Update all other parameters in θ(t+1) using Metropolis-Hasting transition probabilities.
To summarize the posterior distribution based on the the MCMC simulation output,
we proceed by first calculating the maximum a posteriori (MAP) estimate K̂ from the
marginal posterior distribution of K. Conditional on K̂, we find the least squares estimator
Â by the following procedure (Dahl, 2006; Lee et al. , 2015). For any two binary matrices
A,A′ ∈ {0, 1}n×K̂ , we define a distance d(A,A′) = minpiH(A, pi(A′)) where pi(A′) denotes
a permutation of the columns of A′ and H(·, ·) is the Hamming distance of two binary
matrices. A point estimate Â is then obtained as
Â = arg min
A′
∫
d(A,A′)dp(A | Z,Y , K̂).
Both, the integral as well as the optimization can be approximated using the available Monte
Carlo MCMC samples, by carrying out the minimization over A′ ∈ {A(t); t = 1, . . . , T} and
by evaluating the integral as Monte Carlo average. The posterior point estimators of other
parameters in θ are obtained as posterior means conditional on Â. We evaluate the posterior
means using the posterior Monte Carlo samples.
The described MCMC simulation is practicable up to moderately large n, including
n = 1000 in the motivating EHR application. For larger sample sizes, different posterior
simulation methods are needed. We briefly discuss some suggestions in Section 7, and in
Supplementary Material A.
5 Simulation Study
We consider two simulation scenarios. In both scenarios, we generate the patient-disease
matrix A from an IBP(m) model with m = 1 and sample size n = 300. The resulting
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matrix A has K = 6 columns and n = 300 rows, displayed in Figure 5(b). Given K = 6,
we generate a binary symptom-disease matrix B ∈ {0, 1}p×K and a categorical symptom-
disease matrix C ∈ {−1, 0, 1}q×K with p = q = 24 in the following manner. We first set
βjk = 1 for k = 1, . . . , 6 and j = 4(k − 1) + 1, . . . , 4k, γlk = −(−1)k for k = 1, . . . , 6 and
l = 4(k − 1) + 1, . . . , 4k. We then randomly change 10% of the zero entries in B to 1 and
10% of the zero entries in C to +1 or -1. The resulting matrices B and C are shown in
Figures 5(c) and 5(d).
In Scenario I, the observations Z and Y are generated from the sampling model i.e.
equations (4) and (5). To mimic the Chinese EHR data, we assume that we have diagnoses
for the first disease and that we know the related symptoms for the first disease. In the model,
we therefore fix the first column of A, B and C to the truth. In addition, we assume that we
have partial information about the second latent disease: the symptom-disease relationships
are known, but no diagnostic information is available. Accordingly, we will fix the second
columns of B and C, but leave the second column of A as unknown parameters. We ran the
MCMC algorithm described in Section 4 for 5,000 iterations, which took < 5 minutes on a
desktop computer with a 3.5 GHz Intel Core i7 processor. The first half of the iterations are
discarded as burn-in and posterior samples are retained at every 5th iteration afterwards.
Inference summaries are reported in Figure 5. Figure 5(a) shows the posterior distribution
of the number K of latent diseases. The posterior mode occurs at the true value K̂ = 6.
Conditional on K̂, the posterior point estimate Â is displayed in Figure 5(e) with mis-
allocation rate H(Â,A)/(n ·K) = 3%1. Conditional on Â, the point estimates B̂ and Ĉ are
provided in Figures 5(f) and 5(g). The similarity between the heatmaps of the simulation
truth and estimates indicates an overall good recovery of the signal. The error rates in
estimating B and C are 0% and 2%, respectively. We repeat this simulation 50 times. In
96% of the repeat simulations, we correctly identify the number K of latent diseases; in
the remaining 4%, it is overestimated by 1. When K is correctly estimated, the average
mis-allocation rate, error rates for B and C are 3%, 1% and 1% with standard deviation
0.5%, 1% and 1%, respectively. We provide addtional simulation studies in Supplementary
Material A to investigate the performance of DFA with different hyperparameters and with
the alternative prior that was introduced in (3).
1The percentage is computed based on free parameters in A only.
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(h) K̂ across 50 simulations.
Figure 5: Simulation truth and posterior estimates. Panels (a)-(g) are from Scenario I and
Panel (h) is from Scenario II. In the heatmaps, green cells represent 1, white cells 0 and red
cells -1.
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In Scenario II, we use a different simulation truth and generate data {Z˜, Y˜ } from latent
factor models
Z˜ = ΦΛz +Ez and Y˜ = ΦΛy +Ey
with latent factor matrix Φ = A ◦ Φ˜ and loading matrices Λz = B ◦ Λ˜z,Λy = C ◦ Λ˜y where
A,B,C are the same as in Scenario I. The elements of Φ˜, Λ˜z, Λ˜y are i.i.d. Unif(0, 4) and
the errors are i.i.d. standard normal. We then threshold Z˜ and Y˜ to obtain Z and Y at
different levels t > 0:
zij =
 1 if z˜ij > t0 if z˜ij ≤ t and yil =

+1 if y˜il > t
0 if |y˜il| ≤ t
−1 if y˜il < −t.
We applied DFA to {Z,Y } using different values of the threshold t ∈ {1, 2, 3, 4, 5}. Also, we
include no known diseases. Performance deteriorates as t grows. DFA tends to overestimate
the number K̂ of latent factors by 1 to 3 extra factors. After removing those extra factors,
the mis-allocation rate H(Â,A)/(n ·K) is between 9% and 19%. And the error rates for B̂
and Ĉ are between 1% and 17%.
For comparison, we implemented inference also under the sparse latent factor model
(SLFM, Rocˇkova´ & George 2016) to {Z˜, Y˜ }. SLFM assumes a sparse loading matrix and
unstructured latent factors. Therefore, we only report performance in recovering the sparse
structure B and C of the loading matrices Λz and Λy. The penalty parameter λ0 of SLFM
is chosen in an “oracle” way: we fit SLFM with a range of λ0 values and select λ0 that yields
the best performance given the simulation truth. The resulting error rates in estimating B
and C are 11% and 10%, comparable to those of DFA (keeping in mind the oracle choice of
λ0).
We repeat the experiment 50 times for t = 3. The estimated K̂ across 50 simulations
are plotted in Figure 5(h). We observe that DFA tends to overestimate K when model is
misspecified. We report the performance of estimating B̂ and Ĉ based on the best subset
of columns. The mean (standard deviation) error rates in estimating B and C are 8% (4%)
and 9% (3%), respectively. SLFM has slightly higher error rates, 12% (1%) and 11% (1%).
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6 Phenotype Discovery with EHR Data
6.1 Data and preprocessing
We implement latent disease mining for the EHR data introduced in Section 1.1. Using the
reference range for each test item, we define a symptom if the value of an item falls beyond
the reference range. Some symptoms are binary in nature, e.g. low density lipoprotein is
clinically relevant only when it is higher than normal range. Other symptoms are inherently
ternary, e.g. heart rate is symptomatic when it is too high or too low. The 39 testing items
are listed in Table 1 where we also indicate which items give rise to a binary or ternary
symptom.
We extract diagnostic codes for diabetes from the sections “medical history” and “other
current diseases” in the physical examination form. A subject is considered as having di-
abetes if it is listed in either of the two sections. There are 36 patients diagnosed with
diabetes. We fix the first column of A in the PD model according to the diabetes diagnosis.
Moreover, it is known that diabetes is clinically associated with high glucose level. We in-
corporate this prior information by fixing the corresponding entry in the first column of C
in the SD model.
There is additional prior knowledge about symptom-disease relationships. Creatinine, a
waste product from muscle metabolism, is controlled by the kidneys to stay within a normal
range. Creatinine has therefore been found to be a reliable indicator of kidney function.
Elevated creatinine level suggests damaged kidney function or kidney disease. Blood urea
nitrogen (BUN) level is another indicator of kidney function. Like creatinine, urea is also a
metabolic byproduct which can build up if kidney function is impaired. We fix the two entries
(corresponding to creatinine and BUN) of the second column of C to 1 and the rest to 0.
With this prior knowledge, we interpret the second latent disease as kidney disease. Likewise,
it is known that elevated systolic blood pressure and diastolic blood pressure are indicators of
hypertension, and abnormal levels of total bilirubin (TB), aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) are indicators of liver diseases. We fix the corresponding
entries of the third and fourth column of B and C, and interpret the third latent disease as
hypertension and the fourth latent disease as liver disease.
To comply with Chinese policy, we report inference for data preprocessed by a Genera-
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tive Adversarial Network (GAN, Goodfellow et al. 2014), which replicates the distribution
underlying the raw data. GAN is a machine learning algorithm which simultaneously trains
a generative model and a discriminative model on a training dataset (in our case, the raw
EHR dataset). The generative model simulates a hypothetical repetition of the training data,
which is then combined with the original training data to form a merged data set. Mean-
while, the discriminative model tries to distinguish between original data and simulations
in the merged data set. During training, the generative model uses gradient information
from the discriminative model to produce better simulations. Training continues until the
discriminative model can no longer distinguish. After training, the generative model can
be used to generate an arbitrary number of simulations which are similar in distribution to
the original dataset. Any statistical inference in the original data and the replicated data is
identical to the extent to which it relies on low dimensional marginal distributions. In our
case, we generate a simulated dataset of the same size as the raw EHR dataset and then
discretize it using the reference range. A similar approach has been used in Ni et al. (2018).
6.2 Results and interpretations
We ran the MCMC algorithm described in Section 4 for 50,000 iterations. The first half of the
iterations are discarded as burn-in and posterior samples are retained at every 5th iteration
thereafter. Goodness-of-fit and MCMC convergence diagnostics show adequate fit and no
evidence for lack of convergence (Supplementary Material B). Posterior probabilities for the
number K of latent diseases are p(K = 14 | data) = 0.69 and p(K = 15 | data) = 0.24,
respectively, i.e., the maximum a posteriori (MAP) estimate is K̂ = 14. This includes the 4
a priori known diseases as well as 10 newly discovered latent diseases.
Conditional on K̂, the posterior estimates of the PD and SD models are shown as a
heatmap in Figure 7 with green, black and red cells representing 1, 0 and -1, respectively.
The nature of the figure as a single heatmap with two blocks, for PD and SD, respectively,
highlights again the nature of the model as a “double” feature allocation with matching sub-
sets of patients and symptoms. The model allocates both, patients and symptoms, to latent
diseases. As mentioned before, DFA can also be interpreted as an edge-labeled network. We
show the same results as in the heatmap as a bipartite graph in Figure 8(a). The full inferred
model would be a tripartite network, as in the bottom portion of Figure 4. However, we
22
omit the patient nodes in Figure 8(a) , lest the figure would be overwhelmed by the patient
nodes. Instead, we summarize the patient-disease relationships by specifying the font size
of the disease node (triangle, purple font) proportional to the number of linked patients.
Latent diseases are labeled by numbers and a priori known diseases are labeled by name.
Symptoms are shown in black font, with lines showing the links to diseases. Dashed lines are
symptom-disease relationships that are inferred from the data whereas solid lines are fixed
by prior knowledge. Black lines indicate that symptoms are binary. Red (blue) lines indicate
suppression (enhancement) relative to the normal range. Line widths are proportional to
the posterior probabilities of edge inclusion.
We find 239 patients with impaired kidney function or kidney disease, 183 patients with
hypertension and 93 patients with liver disease. The prevalence of kidney disease is slightly
higher than the national average 16.9% (Zhang et al. , 2012) probably because of the elderly
patient population in this study. We caution that the estimated prevalence from our analysis
should be viewed as an estimate for the lower bound of the actual prevalence in the target
patient population because we are not explicitly addressing confounders such as treatment.
For example, our estimated hypertension prevalence (18.3%) is much lower than the national
average 57.3% (Zhang et al. , 2017), probably simply due to successful and widely available
treatment. Individuals who were previously diagnosed with hypertension and comply with
the prescribed medication may not show any symptom (high blood pressure) in the physical
examination.
We identify additional 10 latent diseases with prevalence of 493, 218, 192, 174, 114, 82,
64, 24, 15, and 15 patients. Some of the latent diseases are quite interesting. Latent disease 1
is lipid disorder, associated with high total cholesterol (TC), triglycerides and low density
lipoprotein (LDL). Cholesterol is an organic molecule carried by lipoproteins. LDL is one
type of such lipoproteins, commonly referred to as “bad” cholesterol. At normal levels, TC
and LDL are essential substances for the body. However, high levels of TC and LDL put
patients at increased risk for developing heart disease and stroke. Triglycerides are a type
of fat found in the blood which are produced by the body from excessive carbohydrates and
fats. Like cholesterol, triglycerides are essential to life at normal levels. However, a high
level is associated with an increased chance for heart disease.
Latent disease 3 can be characterized as thrombocytopenia-like disease which causes low
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count of platelets, decreased plateletcrit (PCT) and coefficient of variation of platelet distri-
bution (PDW-CV), and increased mean platelet volume (MPV). Patients with low platelets
may not be able to stop bleeding after injury. In more serious cases, patients may bleed
internally which is a life-threatening condition.
Latent disease 4 is a polycythemia-like disease, associated with elevated mean corpuscular
hemoglobin concentration (MCHC), hemoglobin, erythrocytes and hematocrit (HCT). These
symptoms match exactly the symptoms of polycythemia, a disease that gives rise to an
increased level of circulating red blood cells in the bloodstream. Polycythemia can be caused
intrinsically by abnormalities in red blood cell production or by external factors such as
chronic heart diseases.
Interestingly, like latent disease 4, latent disease 6 is also related to hemoglobin, erythro-
cytes and HCT. However, it is linked with a decrease in these levels; hence we refer to the
disease as anemia.
Latent disease 7 suggests bacterial infection with increased leukocytes, granulocytes (GRA)
and heart rate, and decreased monocytes (MON) and lymphocytes (LYM). The immune sys-
tem, specifically the bone marrow, produces more GRA and leukocytes to fight a bacterial
infection. As a result, the relative abundance of MON and LYM decreases.
Relatedly, latent disease 8 may be caused by viral infection. Viruses can disrupt the
function of bone marrow which leads to low levels of leukocytes and GRA, and high levels
of LYM.
Latent disease 9 is related to allergy with abnormal basophil, GRA and LYM.
Latent disease 10 suggests that a small group of patients may have malnutrition, which
is linked with low blood glucose and anemia-like symptoms such as low corpuscular volume
(MCV) and corpuscular hemoglobin (MCH).
Such automatically generated inference on latent disease phenotypes is of high value for
routine health exams. It helps the practitioners to focus resources on specific patients and
suggests meaningful additional reports. Inference in the statistical model can of course not
replace clinical judgment and needs further validation. But it can provide an important
decision tool to prioritize resources, especially for areas with limited medical support such
as the areas where our data are collected from.
We remark that although there are clear interpretations for most latent diseases found by
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DFA, latent diseases 2 and 5 cannot easily be interpreted as specific diseases. Latent disease 2
is associated with 12 symptoms, which is likely beyond the number of symptoms of any single
disease. Most of the symptoms, such as platelets, leukocytes and lymphocytes, are due to a
weak immune system. Considering the elderly population of this dataset, aging could be a
reasonable cause. Decreased heart rate and low glucose level can also be explained by aging.
Latent disease 5 is linked with elevated systolic blood pressure and glucose. While those two
symptoms may not be simultaneously linked to the same disease, their co-appearance should
not be too surprising because the co-existence of hypertension and diabetes (to which blood
pressure and glucose are known to be linked) is quite common (De Boer et al. , 2017).
We report the estimation of {Wj, ζj}pj=1 and {W−l ,W+l , η−l , η+l }ql=1 in Supplementary
Material B. The estimated baseline weights ζj, η
−
l , η
+
l are significantly smaller than disease-
related weights Wj,W
−
l ,W
+
l .
6.3 A Web application for disease diagnosis
A good user interface is critical to facilitate the implementation of the proposed approach
in the decision process of healthcare providers, and for broad application. Using the R
package shiny (Chang et al. , 2015), we have created an interactive web application (available
at https://nystat3.shinyapps.io/Rshiny/). The application displays disease diagnosis
recommendations for de-identified patients selected by the user. We show the application
for two patients in Figure 6.
6.4 Comparison
As a comparison with results under alternative approaches, we consider inference under
SLFM, applied directly to the blood test results, without converting to binary or ternary
symptoms. The tuning parameter λ0 was set to 1 to approximately match the number
of latent diseases found by DFA. SLFM implements inference on sparse symptom-disease
relationships as shown in Figure 8(b). Although there is no known truth for symptom-
disease relationships, it is difficult to interpret certain links. While uric acid may play some
role in certain diseases, we do not expect it to be related to 5 out of 12 latent diseases. In
addition, both latent diseases 5 and 6 are related to platelets only, which should be collapsed
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Disease Diagnosis Recommendation System with
De-identified Eletronic Health Records
Use the drop-down menu to select patient identification number.
Patient ID#
For selected patient, the disease recommendations are given (in black) together with associated symptoms (in
red). Disease font size is proportional its prevalence.
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For selected patient, the disease recommendations are given (in black) together with associated symptoms (in
red). Disease font size is proportional its prevalence.
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Figure 6: Two examples of the R Shiny web application. Each example is for one patient.
The application interactively displays disease diagnosis recommendations for de-identified
patients selected by the user.
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into one disease. We also ran LSFM with larger λ0 but found similar results. For example,
when λ0 = 10, SLFM identifies 20 latent diseases, 17 of which are associated with uric acid.
These somewhat surprising results may be due to the assumption of normality and linearity
of SLFM, and taking no advantage of prior information.
Next we apply SLFM to the EHR data that are scaled and centered at the midpoint
of each reference range. Choosing λ0 = 13, the algorithm found 10 latent diseases whose
relationships with symptoms are depicted in Figure 8(c). Some findings are consistent with
ours. For example, disease 3 here is similar to disease 1 from DFA. Both are related to LDL
and TC. Likewise, disease 2 is similar to disease 4 from DFA. But some findings remain
difficult to interpret. Six diseases are associated with only one symptom. For instance,
disease 10 is linked to only MPV. However, high or low MPV alone is not of any clinical
importance. It is only of concern if other platelet-related measurements are also out of their
normal ranges. This synergy is well captured by DFA (via disease 3).
As already briefly commented in Section 1, graphical models may be also employed
for finding hidden structures of the symptoms. We run a birth-death MCMC algorithm
(available in the R package BDgraph, Mohammadi & Wit 2015) for 50,000 iterations to learn
a Bayesian graphical model. A point estimate is shown in Figure 8(d). Symptoms that
form cliques of size greater than 3 are marked by circles. Some of the findings are consistent
with those by the DFA. As an illustration, the clique of TC, triglycerides, LDL and HDL is
very similar to latent disease 1 in Figure 8(a). However, although graphical models can find
latent patterns that are not immediately obvious in the correlation structure (Figure 1.1a),
like SLFM, it lacks inference on patient-disease relationships. Moreover, identifying cliques
or other graph summaries as disease is an arbitrary choice.
7 Discussion
We have developed a DFA model for discovery of latent diseases in EHR data. DFA can be
equivalently viewed as categorical matrix factorization or as inference in edge-labeled random
networks. In the EHR data analysis, it is important to include available diagnostic informa-
tion and other prior knowledge, which greatly facilitates identification of latent diseases. We
found that the prevalence of damaged kidney function in our dataset is comparable with, but
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Figure 7: EHR data. The heatmap on top shows the estimated patient-disease relation-
ships Â. The bottom part of the double heatmap shows the estimated symptom-disease
relationships B̂, Ĉ with green, black and red cells representing 1, 0 and -1, respectively.
The columns correspond to diseases and the rows are patients (top portion) and symptoms
(bottom portion).
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(a) SD bipartite network from DFA (b) SD bipartite network from SLFM
(c) SD bipartite network from SLFM with prior information (d) Symptom network from BDgraph
Figure 8: EHR data analysis. (a) Bipartite network for symptom-disease relationships from
DFA. The diseases are represented by triangles with the font size proportional to its popular-
ity (i.e. the number of patients having the disease). Latent diseases are represented by the
numbers (10 latent diseases in total). The symptoms are given in black font and their links
to each disease are represented by the lines. Dashed lines are symptom-disease relationships
inferred from the data whereas solid lines are fixed by prior knowledge. Black lines indicate
the symptoms are binary. Red (blue) lines indicate the disease causes the symptom to be
lower (higher) than normal range. The line width is proportional to its posterior probability
of inclusion. (b) Bipartite network for symptom-disease relationships from SLFM. Latent
diseases are represented by triangles (8 latent diseases in total). (c) Network for symptom-
disease relationships from BDgraph. There are 5 cliques of length greater than 3 in total.
The symptoms that form those cliques are represented by circles.
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slightly higher than the regional average. We also found 10 latent diseases that are related
to lipid disorder, thrombocytopenia, polycythemia, anemia, bacterial and viral infections,
allergy, and malnutrition. Finally, although the proposed DFA model is specifically designed
for disease mining, it could find broader applications in various areas such as education and
psychology (Chen et al. , 2015, 2018).
As demonstrated in Section 6, inference under the DFA model includes inference on
patient-disease relationships. Neither of the alternative approaches, SLFM or graphical
models, include this capability. Knowing patient-disease relationships is crucial in prioritizing
limited medical resources. The proposed inference for the DFA is fully Bayesian. Therefore,
it outputs not only point estimates but also the associated uncertainties through, e.g., the
posterior probability of symptom-disease relationships (reflected by the line width in Figure
8(a)). SLFM is implemented using an Expectation-Maximization (EM) algorithm. It can
quickly get point estimates, but does not include uncertainties.
One of our preprocessing steps is discretizing the original observations into binary or
ternary variables. The main rationale of discretization is two-fold: (1) the reference range
of each test is naturally incorporated; (2) it reduces sensitivity to noise, outliers and distri-
butional assumptions. The downside of discretization, however, is a potential loss of infor-
mation, which can mitigated by increasing the number of categories of the discretization.
Although EHR often involves analysis of big datasets, scalability to large sample size is
not the focus of this paper. We focus on inference for data from a more narrowly restricted
subset equivalent to about a week worth of data. We have shown that such data already
allows meaningful inference on latent diseases. If desired and reasonable, the same approach
could of course be used for larger data sets, but would likely need to be combined with
model extensions to allow for changes in the latent structure, i.e., disease patterns, across
different towns, times and other important factors. Implementation needs computationally
efficient algorithms for posterior inference such as consensus Monte Carlo. In Supplementary
Material A, we summarize a small simulation study assessing the performance of a consensus
Monte Carlo algorithm for larger sample sizes. Computation time for a sample size of 15,000
is under 5 minutes, and summaries of the estimation performance remain comparable to the
MCMC algorithm on small datasets.
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Due to the conditional independence assumption of the sampling model in (4) and (5),
given the model parameters, the proposed DFA can be easily extended to inference on
datasets with missing values by simply ignoring factors in the likelihood that involve miss-
ing values; similar approaches have been studied extensively in the matrix completion and
collaborative filtering literature. One caveat is that it implicitly makes a missing completely
at random assumption. The EHR dataset that we considered here does not have massive
missingness. However, more careful consideration of missingness is needed for application to
EHR data with possibly informative missingness. For instance, with laboratory test results,
a missing test item may suggest a normal result, if one assumed that a test would only be
ordered if based on other symptoms an abnormal level were expected.
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